IDEXX Laboratories, Inc. (IDXX) Holdings Reduced by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 325,741 shares of the company’s stock after selling 2,619 shares during the period. Dimensional Fund Advisors LP owned approximately 0.37% of IDEXX Laboratories worth $50,647,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in IDEXX Laboratories by 0.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after buying an additional 19 shares during the period. National Asset Management Inc. increased its position in IDEXX Laboratories by 2.1% in the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after buying an additional 42 shares during the period. Advisor Group Inc. increased its position in IDEXX Laboratories by 1.1% in the 2nd quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock worth $732,000 after buying an additional 52 shares during the period. QS Investors LLC increased its position in IDEXX Laboratories by 1.5% in the 2nd quarter. QS Investors LLC now owns 4,068 shares of the company’s stock worth $657,000 after buying an additional 60 shares during the period. Finally, Synovus Financial Corp increased its position in IDEXX Laboratories by 2.8% in the 2nd quarter. Synovus Financial Corp now owns 2,249 shares of the company’s stock worth $361,000 after buying an additional 61 shares during the period. 86.61% of the stock is currently owned by institutional investors.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the sale, the chairman now directly owns 1,064,573 shares in the company, valued at $161,091,186.36. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $148.35, for a total value of $2,670,300.00. Following the sale, the chief executive officer now owns 1,064,573 shares in the company, valued at $157,929,404.55. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is currently owned by company insiders.

Several research analysts have commented on IDXX shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research report on Friday, October 6th. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Finally, BidaskClub cut IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $173.67.

Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $166.60 on Friday. The stock has a market capitalization of $14,760.00, a P/E ratio of 54.09, a PEG ratio of 2.23 and a beta of 0.42. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a 1 year low of $115.30 and a 1 year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The business had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 earnings per share. analysts predict that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.

TRADEMARK VIOLATION WARNING: “IDEXX Laboratories, Inc. (IDXX) Holdings Reduced by Dimensional Fund Advisors LP” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/06/idexx-laboratories-inc-idxx-holdings-reduced-by-dimensional-fund-advisors-lp.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply